NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S: Financial statements 2017
CVR: 33249098
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S (CVR 33249098) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 2,860,959 and a net result of DKK 1,971,520 compared with DKK 11,052,541 the year before. That is a decrease of 82.1% compared with the year before. Equity in the 2017 report amounted to DKK 3,005,838. The solvency ratio was 39.5%.
- Gross Profit
- DKK 2,860,959
- Profit/Loss
- DKK 1,971,520
- Equity
- DKK 3,005,838
- Total Assets
- DKK 7,609,558
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 2.9 mio. | 2 mio. | 3 mio. | - |
| 2016 | - | 16 mio. | 11.1 mio. | 12 mio. | - |
| 2015 | - | 60.4 mio. | 45.4 mio. | 46 mio. | - |
| 2014 | - | 42 mio. | 32.4 mio. | 38.6 mio. | - |
| 2013 | - | 4.2 mio. | 3.2 mio. | 6.2 mio. | - |
Official annual report
Keep an eye on NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2016. Gross profit came to DKK 15,990,692, and the net result was DKK 11,052,541.
About NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S was a Danish company of the type Aktieselskab based in Herlev, founded in 2010. The company has been dissolved on 25 May 2021. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. According to the 2019 annual report, the company had an average of 0 employees. In 2019, the company reported a gross profit of DKK 248,136 and a net result of DKK 164,772 compared with DKK 954,488 the year before. Equity in the 2019 report amounted to DKK 725,098.